Merck & Co., Inc.
Merck & Co., Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
2 of 4 strong
The short version
- Process Solutions expects normalized underlying growth around 10% post exceptional Q1 effects; some stocking effects may persist into Q2 but will lessen in H2 2026 (Page 7, 10, 14). - Merck expects underlying growth for Process Solutions to normalize around 10% midterm (Page 7, 10). - Healthcare aims to increase R&D spend from ~21% to around 25% gradually, maintaining EBITDA pre-margin above 30% (Page 7). - Midterm guidance for CME (part of Healthcare) anticipates mid-single-digit organic growth from 2026 onward, with second half 2026 expected to improve (Page 13). - Fertility segment targets mid-single-digit growth midterm, with stabilization and improved momentum expected for Gonal F post-Q2 2026 price cut annualization (Page 13). - The company remains confident in midterm growth targets, with guidance raised after a strong Q1 2026 performance and more visibility on macro trends (Page 1, 6). - EBITDA pre margin for Q1 was high at 35%, but expected to be lower for the rest of 2026 due to launch investments and U.S.
From Merck & Co., Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Process Solutions expects normalized underlying growth around 10% post exceptional Q1 effects; some stocking effects may persist into Q2 but will lessen in H2 2026 (Page 7, 10, 14).
- Healthcare R&D spend targets gradually increasing from ~21% to around 25%, supporting midterm growth beyond 2030 (Page 10).
- Fertility business aims for mid-single-digit growth midterm, with stabilization and improved momentum expected from Q2 2026 onward after previous pricing headwinds (Page 13).
- CME franchise targets mid-single-digit organic growth in 2026, with stronger performance anticipated in H2 (Page 13).
- Life Sciences & Electronics expected to be well on track with midterm guidance; growth acceleration visibility improving for 2027 and beyond (Page 9, 10).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Merck & Co., Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Merck is strategically focusing on building platform capabilities to enhance collaboration across businesses, which supports scalability and speed in implementation.
- The company is increasing R&D investments, particularly in ramping up extensive Phase III programs, aiming for an R&D-to-sales ratio approaching 25% in the midterm while maintaining EBITDA margin above 30%.
- M&A and in-licensing are key growth levers across all businesses, with a broadened scope targeted at strengthening product offerings and accelerating integrated solutions, especially in early to mid-stage healthcare pipeline development.
- Investments are planned to shift product portfolios towards integrated workflow solutions, expanding beyond stand-alone products to end-to-end integrated offerings in areas like bioprocessing and advanced electronics.
2 more points management made on capital expenditure plans
Fundraising & Capital Structure
See what Merck & Co., Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The order book for Process Solutions is described as very solid and strong.
- The book-to-bill ratio is noted to be far above 1, indicating more orders pending than shipped.
- There is strong visibility into the order book through detailed reports that slice by customer, region, product type, and order timing (0-1 month, 1-3 months, etc.).
- Exceptional factors influenced Q1 orders, such as operational efficiency, new customer projects, and stocking by APAC customers.
- Some exceptional effects may persist in Q2 but will lessen in the second half of the year.
2 more points management made on order book & pipeline
Frequently Asked Questions
What were Merck & Co., Inc. Q2 FY26 results?
- Process Solutions expects normalized underlying growth around 10% post exceptional Q1 effects; some stocking effects may persist into Q2 but will lessen in H2 2026 (Page 7, 10, 14). - Merck expects underlying growth for Process Solutions to normalize around 10% midterm (Page 7, 10). - Healthcare aims to increase R&D spend from ~21% to around 25% gradually, maintaining EBITDA pre-margin above 30% (Page 7). - Midterm guidance for CME (part of Healthcare) anticipates mid-single-digit organic growth from 2026 onward, with second half 2026 expected to improve (Page 13). - Fertility segment targets mid-single-digit growth midterm, with stabilization and improved momentum expected for Gonal F post-Q2 2026 price cut annualization (Page 13). - The company remains confident in midterm growth targets, with guidance raised after a strong Q1 2026 performance and more visibility on macro trends (Page 1, 6). - EBITDA pre margin for Q1 was high at 35%, but expected to be lower for the rest of 2026 due to launch investments and U.S.
What is Merck & Co., Inc. share price analysis?
Merck & Co., Inc. currently shows a neutral. The stock trades at a P/E of N/A with a market cap of $296,107. Investors should review the full earnings analysis for detailed insights.
Is Merck & Co., Inc. planning capital expenditure?
- Merck is strategically focusing on building platform capabilities to enhance collaboration across businesses, which supports scalability and speed in implementation.
Keep Merck & Co., Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.